
RenovoRx (RNXT) Stock Forecast & Price Target
RenovoRx (RNXT) Analyst Ratings
Bulls say
RenovoRx Inc. has demonstrated a notable increase in revenue, reporting $422K in Q2, a substantial rise from $197K in Q1. The company anticipates continued growth, projecting revenues to reach approximately $1.3 million in 2025 and $4.5 million in 2026, reflecting the potential demand for its innovative therapy platform. As a clinical-stage biopharmaceutical firm, RenovoRx is positioned to significantly enhance its financial performance as its proprietary treatments advance in development and market adoption increases.
Bears say
RenovoRx Inc. is facing significant challenges, as evidenced by a reported revenue of $0.4 million against a net loss of $2.9 million, which translates to an earnings per share (EPS) of $(0.08). The company's product development is focused on treating pancreatic cancer, one of the deadliest cancers with a dismal 5-year survival rate of just 12%, highlighting the high unmet medical need but also significant market risk. Despite some potential growth prospects, the current financial losses and the harsh realities of the oncology market contribute to a negative outlook on the company's stock.
This aggregate rating is based on analysts' research of RenovoRx and is not a guaranteed prediction by Public.com or investment advice.
RenovoRx (RNXT) Analyst Forecast & Price Prediction
Start investing in RenovoRx (RNXT)
Order type
Buy in
Order amount
Est. shares
0 shares